ERBB2 and breast carcinoma: This is in accordance with international guidelines [8, 9, 22] which currently recommend chemotherapy only in high-risk breast cancer patients: namely triple negative, HER2 positive, majority of luminal B and exceptionally high-risk luminal A breast cancers.